Fractyl Health
GUTS on Nasdaq. Fractyl Health develops treatments for people with obesity and type 2 diabetes. Market value $726m.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-12.49 of spare cash last year. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$4.57 a share, 6% above its 1-year low
Over the past year the price has ranged from $4.33 to $29.34.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | ||
| Revenue | $93,000 | $0 |
| Operating margin | ||
| Operating margin | -100571.0% | n/a |
| Debt to equity | ||
| Debt to equity | n/a | n/a |
| Shares outstanding | ||
| Shares outstanding | 0.14bn | 0.16bn |
Health checks
- Free cash flow positive0 of 2 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)2 of 7 checks we could run
- Profit backed by cash (accruals)No
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 16% more shares since 2024
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $26 million, compared with a loss of $28 million a year ago.
- 223% more shares than a year ago. Each share owns a bit less of the company.
| Quarter to | Amount |
|---|---|
| September 2024 | -$23m |
| December 2024 | -$25m |
| March 2025 | -$24m |
| June 2025 | -$28m |
| September 2025 | -$46m |
| December 2025 | -$44m |
| March 2026 | $9m |
| June 2026 | -$26m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 24 March 2026
- Next quarterly (estimated, 10-Q)
- 9 November 2026
Who owns it
None of the long-term investors we follow own it. 76 funds in all.
Largest holders overall
- Nantahala Capital Management$18mAdded
- Catalio Capital Management, LP$5mAdded
- Vanguard Capital Management$5mAdded
- Bank of America$5mAdded
- Pale Fire Capital SE$4mCut
- General Catalyst Group Management$4m
- Deer Management$4m
- Maverick Capital$3m
- M28 Capital Management LP$1m
- BlackRock$1mCut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
7 investors own more than 5%.
- Nantahala Capital Management, LLCPassive investorat least 10.0%0.0 pts(filed with 2 related holders)Since 31 March 2026
- Deer VII & Co. Ltd.Passive investorat least 9.9%(filed with 3 related holders)Since 31 December 2024
- Alyeska Investment Group, L.P.Passive investorat least 5.0%−4.7 pts(filed with 2 related holders)Since 31 December 2025
- 683 Capital Management, LLCPassive investorat least 4.8%−0.5 pts(filed with 2 related holders)Since 31 March 2026
- Ajay RoyanPassive investorat least 4.7%(filed with 6 related holders)Since 31 December 2025
- HCC Manager LLCPassive investorat least 3.4%(filed with 1 related holder)Since 4 February 2026
- Maverick Capital, Ltd.Passive investorat least 3.1%(filed with 2 related holders)Since 30 September 2025
- BlackRock, Inc.Passive investorSold down below 5%Since 31 March 2025
- SilverArc Capital Management, LLCPassive investorSold down below 5%Since 31 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Nantahala Capital Management, LLC Passive investor | at least 10.0%0.0 pts (filed with 2 related holders) | 31 March 2026 | |
Deer VII & Co. Ltd. Passive investor | at least 9.9% (filed with 3 related holders) | 31 December 2024 | |
Alyeska Investment Group, L.P. Passive investor | at least 5.0%−4.7 pts (filed with 2 related holders) | 31 December 2025 | |
683 Capital Management, LLC Passive investor | at least 4.8%−0.5 pts (filed with 2 related holders) | 31 March 2026 | |
Ajay Royan Passive investor | at least 4.7% (filed with 6 related holders) | 31 December 2025 | |
HCC Manager LLC Passive investor | at least 3.4% (filed with 1 related holder) | 4 February 2026 | |
Maverick Capital, Ltd. Passive investor | at least 3.1% (filed with 2 related holders) | 30 September 2025 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 31 March 2025 | |
SilverArc Capital Management, LLC Passive investor | Sold down below 5% | 31 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 5 insiders bought $187,052 of shares on the open market.
- BRADLEY WILLIAMDirectorBought
- Date
- 14 September 2026
- Shares
- 64,516
- Price
- $0.62
- Value
- $39,903
- Royan AjayDirectorBought
- Date
- 12 June 2026
- Shares
- 23,000
- Price
- $0.85
- Value
- $19,550
- BRADLEY WILLIAMDirectorBought
- Date
- 10 June 2026
- Shares
- 68,493
- Price
- $0.73
- Value
- $50,000
- Sheffield IanDirectorBought
- Date
- 10 June 2026
- Shares
- 35,000
- Price
- $0.73
- Value
- $25,550
- Rajagopalan HarithChief Executive Officer, DirectorBought
- Date
- 10 June 2026
- Shares
- 25,000
- Price
- $0.73
- Value
- $18,250
- Smith Weber LaraChief Financial OfficerBought
- Date
- 8 June 2026
- Shares
- 20,000
- Price
- $0.69
- Value
- $13,800
- Rajagopalan HarithChief Executive Officer, DirectorBought
- Date
- 4 December 2025
- Shares
- 10,416
- Price
- $1.92
- Value
- $19,999
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 14 September 2026 | BRADLEY WILLIAM Director | Bought | 64,516 | $0.62 | $39,903 |
| 12 June 2026 | Royan Ajay Director | Bought | 23,000 | $0.85 | $19,550 |
| 10 June 2026 | BRADLEY WILLIAM Director | Bought | 68,493 | $0.73 | $50,000 |
| 10 June 2026 | Sheffield Ian Director | Bought | 35,000 | $0.73 | $25,550 |
| 10 June 2026 | Rajagopalan Harith Chief Executive Officer, Director | Bought | 25,000 | $0.73 | $18,250 |
| 8 June 2026 | Smith Weber Lara Chief Financial Officer | Bought | 20,000 | $0.69 | $13,800 |
| 4 December 2025 | Rajagopalan Harith Chief Executive Officer, Director | Bought | 10,416 | $1.92 | $19,999 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Fractyl Health’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 9 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“As a result, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year after the date that these financial statements are issued.”
Show the full paragraph
The Company has financed its operations to date primarily through its equity and debt financings. The Company has a history of operating losses and had an accumulated deficit of $ 572.6 million as of June 30, 2026, and management expects continuing operating losses in the future. As of June 30, 2026 , the Company had available cash and cash equivalents of $ 47.1 million. Management believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into early 2027, through multiple key clinical and regulatory milestones. However, these existing cash resources are not expected to be sufficient to fund the Company’s current operating plan for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year after the date that these financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
From the 10-Q filed 10 August 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.